Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.74 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.74 |
| ▸ | STAT3 | P40763 | 2/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.68 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.68 |
| ▸ | GSK3B | P49841 | 3/20 | 0.61 |
| ▸ | BRD4 | O60885 | 4/20 | 0.60 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.60 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.57 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24391027 | 0.99 | CRBN (0.73) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL20327724 | 0.99 | CRBN (0.73) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL24391010 | 0.98 | CRBN (0.74) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL20291122 | 0.96 | CRBN (0.71) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL20153967 | 0.96 | CRBN (0.70) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL26320196 | 0.96 | STAT3 (0.76) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL20154034 | 0.95 | CRBN (0.70) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL23584014 | 0.95 | CRBN (0.69) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL23584020 | 0.93 | CRBN (0.71) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL24243563 | 0.93 | CRBN (0.71) | CRBNDDB1STAT3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11046954-B2 | Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20180179522-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180169109-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169109-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | NFATC1, GZMB, ICOS | CRBN 97/4885DDB1 940/4885STAT3 601/4885 |
| US-20180179522-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | PSMG3, MYCBP, DBN1 | CRBN 138/4885DDB1 26/4885STAT3 2603/4885 |
| US-11046954-B2 | Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses | NFATC1, GZMB, ICOS | CRBN 97/4885DDB1 940/4885STAT3 601/4885 |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | PSMG3, MYCBP, DBN1 | CRBN 138/4885DDB1 26/4885STAT3 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.